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Summary
The worldwide incidence of skin cancer (especially non-melanoma skin cancer)
has risen dramatically over the last decades. Skin cancer, including pre-malignant
lesions, is becoming a chronic disease. Adjustments in skin cancer health 
care need to be made. A disease management system for skin cancer is
mandatory in order to avoid waiting lists and insure adequate treatment 
quality with ever growing numbers of patients requiring treatment. At the
Catharina Hospital Eindhoven adjustments are being made on several levels
of the dermato-oncology unit in collaboration with Eindhoven University of
Technology. The model combines technological improvements, training
health care workers, training of general practitioners and prevention of skin
cancer. We discuss our ideas and clinical experiences with managing a dermato-
oncology unit.
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Introduction
The worldwide incidence of skin cancer
(especially non-melanoma skin cancer)
has risen dramatically over the last
decades [1, 2].
Estimates show that one in five persons
will be diagnosed with skin cancer in
their life [1]. This is probably an 
underestimate because adequate registra-
tion of these cancers is often lacking 
in many countries [2]. Traditionally, 
the incidence is highest in the elderly
(> 65 years), 438 per 100 000 person-
years [3]. There is a world-wide rise in
skin cancer incidence of at least 5 % 
annually [3]. This increase will continue
for at least two decades, and is caused 
by a growing aging population as well as
an increase of UV exposure (solar and 
artificial) [3].
A second patient group consists of organ
transplant patients who develop multiple
lesions. Although rates differ across 
various countries, the number of patients
receiving organ transplants is increasing.
In the Netherlands 1 100 persons had
organ transplants in 2007, which is an
increase of 28 % compared to 2006 [4].
Since the improvement of graft survival
has resulted in increased survival for trans-
plant patients, the number of survivors
has increased accordingly. However, this
phenomenon is paired with a longer du-
ration of immune suppressive medica-
tion resulting in more skin malignancies
[5, 6]. Nearly 50 % of all renal transplant
patients develop skin cancers within 
20 years after transplantation [6].
The younger adult population (15–34
years) is a third large patient group. 
In this group, it is predicted that skin 
cancer incidence will double from 322
incident cases in 2000 to 676 incident
cases in 2015 [3].
With a population that is aging and a
skin cancer incidence that is on the rise
in the younger population, a growing
amount of patients will be confronted
with multiple new tumours for the rest
of their lives. In addition, many of these
patients have skin pre-malignancies as
well [7–10]. Skin cancer and pre-malig-
nancy are becoming a chronic disease
with a disease burden comparable to
other chronic diseases. 
The increased prevalence has resulted in
many dermatologists needing to allocate
more of their time to these problems. An
evaluation of the diagnosis-treatment
codes of a large outpatient dermatology
clinic at the Catharina Hospital Eind-
hoven in the Netherlands shows that
over 50 % of dermatologists’ time is
spent on skin cancer and pre-malignant
skin lesions. This is only the tip of the
iceberg. If no changes are planned for the
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health care system of the Netherlands,
this will result in dermatologists’ work
being limited to skin malignancies and
pre-malignancies, resulting in less atten-
tion paid to other dermatology patients.
Consequently, adjustments in skin can-
cer health care need to be made. A dis-
ease management system for skin cancer
is mandatory in order to avoid waiting
lists and ensure adequate treatment quality
with ever growing numbers of patients
requiring (surgical) treatment. 
In the literature, few articles are available
about the management of a dermatology
practice. The latest articles date back to
2000, discussing general adjustments for
dermatology clinics to achieve the best
possible business outcome [11–13]. No
literature is available about running a
dermato-oncology unit, i. e. how to 
deal with an increasing amount of skin
cancer patients while maintaining quality
of care.
Few articles describe specialty clinics for
the dermatologic care of solid-organ
transplant patients [14, 15]. They em-
phasize the importance of an organized
and firmly established clinic model to al-
low proactive and ongoing care for these
patients. Close communication with the
team of transplant physicians, education
of other health care providers, an effec-
tive scheduling mechanism and patient
education are all described as key points
to provide the best care.
At the Catharina Hospital Eindhoven,
adjustments are being made on several
levels of the dermato-oncology unit. In
this so called “disease management sys-
tem for skin cancer”, we are working
closely together with the Eindhoven
University of Technology. In the past 
5 years it has shown to be possible to ac-
commodate an increase of 20 % in skin
cancer patients at the Catharina Hospi-
tal. Workflow technology will help in
further reorganizing this dermato-oncol-
ogy unit so that it will be capable of facil-
itating an annual increase of at least 5 %
of skin cancer patients. We will discuss
our ideas and clinical experiences with
respect to developing the disease man-
agement system for skin cancer.
Prevention
First of all, prevention is one of the most
important strategies to influence the rap-
idly increasing incidence of skin cancer.
Prevention campaigns should increase
attention to young children and their
parents, with a focus on UV protection
throughout life. Prevention however, will
not influence the rising skin cancer inci-
dence and prevalence on a short term ba-
sis. As a result – unfortunately – it is not
an important subject for health care in-
surances. The sense of urgency among
dermatologists that skin cancer is be-
coming an expensive disease (in the U.S.
skin cancer has taken the fifth position
with respect to cancer costs) [16], has
not resulted in providing financial 
stimulus for prevention campaigns by
governments nor insurance companies.
Primary prevention and secondary pre-
vention should go hand in hand and der-
matologists should play an important
role in educating patients and future pa-
tients in how to reduce the risk of
chronic skin malignancy.
General practitioners
General practitioners (GP) should be
trained to recognize skin malignancies
and diagnose them at an early stage. This
will lead to smaller skin malignancies,
which are less difficult and less expensive
to treat than large malignancies [17]. We
are preparing a large scale training pro-
gramme for GP to recognize and treat
actinic keratosis (AK). In an unpub-
lished survey among GP, it was stated
that they have difficulties in recognizing
AK and find it important to be trained
and supported in recognizing and treat-
ing AK. Many patients with chronic skin
(pre)malignancy could be followed by
the GP and/or a nurse practitioner who
is stationed at the GP office once a week.
It will be sufficient to see these patients
in the dermato-oncology clinic only if
the GP is in doubt about the diagnosis, if
a squamous cell carcinoma is suspected
(and early excision is required) or if there
are severe adverse events occurring dur-
ing treatment. Teledermatology could
help to improve efficiency of patient re-
ferrals and patient care [18, 19].
GP should also be involved in preven-
tion campaigns and in the after-care of
treated patients (for instance, remove
stitches and inform patients of complete
or incomplete tumour-removal). A con-
tinuous medical education programme
for GP (e-learning and training) will re-
duce unnecessary or late referrals. 
Specially-trained nurses
We started in 2004 with a training pro-
gramme for dermato-oncology nurses.
This resulted in special trained dermato-
oncology nurses, nurse practitioners and
physician assistants. Depending on their
educational background and clinical ex-
perience, they perform multiple tasks to
relieve the workload for the dermatolo-
gists in our unit.
Biopsies and small standard excisions, in-
cluding the closure of small defects, are
performed by these employees under the
supervision of a dermatologist. They also
perform photodynamic therapy and
cryotherapy, give local anesthesia, re-
move stitches, and give information on
(primary and secondary) prevention and
treatments. They inform the patient
about the diagnosis, treatment and fol-
low-up. Workflow management helps to
reduce the number of hospital visits; der-
mato-oncology nurses are available to
give adjuvant information (mostly by
email) in case a patient has a question. A
dermatologist is available in the back-
ground if needed. 
Nurse care management interventions
have been shown to improve medical,
psychosocial and lifestyle outcomes in
patients with chronic diseases such as di-
abetes [20]. Taylor et al. show that nurse
care managers, working closely with the
patients’ GP and using evidence based
algorithms, can improve medical out-
comes, without increasing physician vis-
its [20]. A review of a nurse-led care in
dermatology concludes that nurses are
managing and treating a number of der-
matological conditions, primarily using
treatment protocols. Patients report vari-
ous benefits such as faster access to treat-
ment, reduction in referral to the general
practitioner or dermatologist and an in-
crease in knowledge of their condition
[21].
Information technology
To improve work efficiency, quality of
care and patient satisfaction, a modern
information technology system is
needed. Together with Eindhoven Uni-
versity of Technology, we are shaping an
information technology system that will
allow us to consult, manipulate and re-
trieve patient-related data. Further-
more, the system will be pro-active and
allow diagnostic and treatment advice
for clinically diagnosed lesions at any
time.
Over the past years, insights have been
gained on how such clinical decision
support could be effectively integrated
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into the care process [22]. The system
will also be developed such that commu-
nication amongst the health care teams is
facilitated. For instance, assisting nurses
in ascertaining which actions need to be
executed or have already been completed
for patients [23]. The potential of this
technology has not been fully exploited
in the healthcare domain in general, and
certainly not for skin cancer manage-
ment [24].
By using a workflow system at our der-
mato-oncology unit, it was possible to
increase the number of photodynamic
treatments performed by a dermato-
oncology nurse from 7 to 10 per day.
Workflow technology will also be bene-
ficial to further streamline the allocation
of work, to monitor work in progress,
and analyze effectiveness of treatment
patterns for patient subgroups.
A final improvement resulting from the
application of IT is the use of email-
 contact for patients with their dermato-
oncology nurse. This reduces the number
of telephone-calls (which are more time-
consuming then emails) and improves
the patient-satisfaction.
Diagnosis and One-stop-shop
Instant diagnosis by histopathology
should be available to diminish the
number of hospital visits and telephone
calls. In the Catharina Hospital we are
using frozen sections on biopsies on
clinically well-defined basal cell carci-
noma (BCC) taken immediately at the
first visit. The frozen sections are exam-
ined by one of the Mohs surgeons as
well as a pathologist to confirm the di-
agnosis. Patients are informed about the
diagnosis the same day. If planned
properly, an excision could take place
immediately by a physician assistant. In
other cases, Mohs micrographic surgery
(MMS) or PDT can be performed im-
mediately after and follow-up appoint-
ments can be planned by the trained
nurse.
By this so-called “one-stop-shop diagno-
sis and treatment”, less appointments
are needed (reducing the burden on the
healthcare system), and on the other
hand it will improve quality of medical
care (especially for most elderly patients
and their relatives less hospital visits are
extremely welcome). For pigmented le-
sions and squamous cell carcinoma, di-
rect excision is possible on a daily basis
as well.
Medical treatment
Various treatment modalities are avail-
able for dermato-oncology patients. Der-
matologists need to use all these modali-
ties in an efficient way. Treatments can
easily be combined [25–29]. Periods that
patients are in the hospital need to be
used as efficiently as possible. While pa-
tients are waiting in between rounds of
MMS for their aggressive BCC in the
face, we perform PDT for AK or superfi-
cial BCC.
For patients with very extensive skin ma-
lignancies, like patients with the nevoid
basal cell carcinoma syndrome, we per-
form mega-sessions under general anes-
thesia. In these treatment sessions, we
treat multiple lesions with various tech-
niques (MMS, surgical excision, PDT)
[30, 31].
In addition, several treatments exist that
can be used by the patient at home.
This will of course diminish the work-
load at the outpatient clinic. Patients
are able to contact a nurse practitioner
or special trained nurse if they have
questions about the treatment, or about
side effects.
Finally, treatment options need to be
based on optimal treatment results. Un-
fortunately, for surgical treatments ran-
domized controlled trials on margins,
histopathological examination and other
parameters are limited. Recently, 5-year
results on MMS have become available
and these indicate fewer recurrences after
MMS for recurrent facial BCC [32]. In
the past, MMS was considered to be
time-consuming, and this was a reason
not to perform MMS. By incorporating
a histopathology lab into the dermatol-
ogy clinic, it is possible to increase effi-
ciency for MMS. In the Catharina Hos-
pital we perform 6 MMS procedures
daily, along with multiple excisions (for
pigmented lesions, squamous cell carci-
noma), PDT and one-stop-shop for
BCC.
Conclusion
Skin cancer, including pre-malignant le-
sions, is becoming a chronic disease. The
enormous increase in skin cancer will
force dermatologists to make adjust-
ments in how they run their practice.
The disease management system that is
set up at the Catharina Hospital Eind-
hoven is one of the ways to provide an
answer to the ever increasing number of
patients that need to be treated for skin
cancer, but an effective one. The system,
which is still expanded and developed,
combines technological improvements
(for instance workflow technology to
maximize the number of MMS or PDT
treatments) with training of health care
workers (nurses, nurse practitioners,
physician assistants, GP and others). Ad-
ditionally, there is a focus on early recog-
nition of lesions by patients and GP, as
well as on prevention of skin cancer.
Finally, the use of one-stop-shop (by the
use of frozen sections, already available
for MMS) can furthermore increase 
efficiency. We hope that our ideas and
experiences can serve as an inspiration
for setting up other dermato-oncology
units. <<<
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